Cambridge Investment Research Advisors, Inc. Gain Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $36.4 Billion
- Q3 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 318,645 shares of GANX stock, worth $901,765. This represents 0.0% of its overall portfolio holdings.
Number of Shares
318,645
Previous 179,500
77.52%
Holding current value
$901,765
Previous $323,000
74.61%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding GANX
# of Institutions
42Shares Held
5.02MCall Options Held
10.3KPut Options Held
0-
Jones Financial Companies Lllp677KShares$1.92 Million0.0% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.67 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.6 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA534KShares$1.51 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il374KShares$1.06 Million0.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $33.6M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...